Thomas A. Lanz

Thomas A. Lanz

Auto-generated profile, based on publicly available information

Thomas A. Lanz

Pfizer Inc., Drug Safety R&D, Groton, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RMRoberto Di Maio
Roberto Di Maio
EHEric K. Hoffman
Eric K. Hoffman
EREmily M. Rocha
Emily M. Rocha
MKMatthew T. Keeney
Matthew T. Keeney
LSLaurie Sanders
Laurie Sanders
JGJ. Timothy Greenamyre
J. Timothy Greenamyre
Wild-type LRRK2 is activated in nigrostriatal dopamine neurons in idiopathic Parkinson’s disease and plays a pathogenic role in this neurodegenerative disorder.

6 February 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
BMBrooke H. Miller
Brooke H. Miller
ZZZane Zeier
Zane Zeier
LXLi Xi
Li Xi
TLThomas A. Lanz
Thomas A. Lanz
SDShibing Deng
Shibing Deng
Claes WahlestedtClaes Wahlestedt
Claes Wahlestedt
Schizophrenia is characterized by affective, cognitive, neuromorphological, and molecular abnormalities that may have a neurodevelopmental origin. MicroRNAs (miRNAs) are small noncoding RNA sequences critical to neurodevelopment and adult neuronal processes by coordinating the activity of multiple genes within biological networks. We examined the expression of 854 miRNAs in prefrontal cortical tissue from 100 control, schizophrenic, and bipolar subjects. The cyclic AMP-responsive element binding- and NMDA-regulated microRNA miR-132 was significantly down-regulated in both the schizophrenic discovery cohort and a second, independent set of schizophrenic subjects. Analysis of miR-132 target gene expression in schizophrenia gene-expression microarrays identified 26 genes up-regulated in schizophrenia subjects. Consistent with NMDA-mediated hypofunction observed in schizophrenic subjects, administration of an NMDA antagonist to adult mice results in miR-132 down-regulation in the prefrontal cortex. Furthermore, miR-132 expression in the murine prefrontal cortex exhibits significant developmental regulation and overlaps with critical neurodevelopmental processes during adolescence. Adult prefrontal expression of miR-132 can be down-regulated by pharmacologic inhibition of NMDA receptor signaling during a brief postnatal period. Several key genes, includingDNMT3A,GATA2, andDPYSL3, are regulated by miR-132 and exhibited altered expression either during normal neurodevelopment or in tissue from adult schizophrenic subjects. Our data suggest miR-132 dysregulation and subsequent abnormal expression of miR-132 target genes contribute to the neurodevelopmental and neuromorphological pathologies present in schizophrenia.

23 May 2019 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
TLThomas A. Lanz
Thomas A. Lanz
VRVeronica Reinhart
Veronica Reinhart
MSMark J. Sheehan
Mark J. Sheehan
SRStacey J. Sukoff Rizzo
Stacey J. Sukoff Rizzo
SBSusan E. Bove
Susan E. Bove
RKRobin J. Kleiman
Robin J. Kleiman
Psychiatric disorders such as schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD) arise from complex interactions between genetic and environmental factors. Common genetic variants associated with multiple psychiatric disorders suggest that shared genetic architecture could contribute to divergent clinical syndromes. To evaluate shared transcriptional alterations across connected brain regions, Affymetrix microarrays were used to profile postmortem dorsolateral prefrontal cortex (DLPFC), hippocampus, and associative striatum from 19 well-matched tetrads of subjects with SCZ, BD, MDD, or unaffected controls. SCZ subjects showed a substantial burden of differentially expressed genes across all examined brain regions with the greatest effects in hippocampus, whereas BD and MDD showed less robust alterations. Pathway analysis of transcriptional profiles compared across diagnoses demonstrated commonly enriched pathways between all three disorders in hippocampus, significant overlap between SCZ and BD in DLPFC, but no significant overlap of enriched pathways between disorders in striatum. SCZ samples showed increased expression of transcripts associated with inflammation across all brain regions examined, which was not evident in BD or MDD, or in rat brain following chronic dosing with antipsychotic drugs. Several markers of inflammation were confirmed by RT-PCR in hippocampus, including S100A8/9, IL-6, MAFF, APOLD1, IFITM3, and BAG3. A cytokine ELISA panel showed significant increases in IL-2 and IL-12p70 protein content in hippocampal tissue collected from same SCZ subjects when compared to matched control subjects. These data suggest an overlapping subset of dysregulated pathways across psychiatric disorders; however, a widespread increase in inflammation appears to be a specific feature of the SCZ brain and is not likely to be attributable to chronic antipsychotic drug treatment.

1 August 2003 in Neurobiology of Disease
Verified
Journal Article
Closed access
TLT.A Lanz
T.A Lanz
DCD.B Carter
D.B Carter
KMK.M Merchant
K.M Merchant

1 June 2003 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
TLThomas A. Lanz
Thomas A. Lanz
CHCarol S. Himes
Carol S. Himes
GPGiovanni Pallante
Giovanni Pallante
LALisa Adams
Lisa Adams
SYShinji Yamazaki
Shinji Yamazaki
KMKalpana M. Merchant
Kalpana M. Merchant
Acute, s.c. administration of a γ-secretase inhibitor, N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT), to young PDAPP mice dose dependently decreases cortical amyloid-β (Aβ). The present studies replicated these findings in Tg2576 mice and examined further whether DAPT would reduce cerebrospinal fluid (CSF) Aβ comparably in young (plaque-free) and aged (plaque-bearing) mice. In the first study, vehicle or DAPT (10, 30, or 100 mg/kg s.c.) administered to young Tg2576 mice (6 months old) dose dependently reduced Aβ peptide levels in the cortex as seen previously in the PDAPP mice. Additionally, a dose-dependent decrease in plasma Aβ levels was evident. The same dosing regime was applied next to aged mice (17 months old) to assess Aβ changes in the CSF in addition to plasma and brains. DAPT dose dependently reduced Aβ levels in the CSF and plasma, but not in the brain wherein Aβ levels were 400 to 500 times higher than those in young mice, consistent with a large pool of Aβ extracted from amyloid deposits. In subsequent studies, effects of oral DAPT (100 or 200 mg/kg) were examined concurrently in young and aged mice. DAPT reduced Aβ levels in CSF and plasma to a similar extent at both ages. In contrast, DAPT reduced brain Aβ levels primarily in young mice, with minimal effects in aged mice. These results demonstrate that Aβ levels in CSF and plasma decrease dose dependently after γ-secretase inhibition, and this response is not affected by amyloid plaque burden. We conclude that CSF and plasma Aβ may offer a clinically applicable, mechanism-based biomarker for inhibitors of Aβ production.

1 May 2015 in Neurobiology of Disease
Verified
Journal Article
Closed access
VRVeronica Reinhart
Veronica Reinhart
SBSusan E. Bove
Susan E. Bove
DVDmitri Volfson
Dmitri Volfson
DLDavid A. Lewis
David A. Lewis
RKRobin J. Kleiman
Robin J. Kleiman
TLThomas A. Lanz
Thomas A. Lanz